These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20399641)

  • 1. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia.
    Boschelli F; Arndt K; Gambacorti-Passerini C
    Eur J Cancer; 2010 Jul; 46(10):1781-9. PubMed ID: 20399641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
    Keller G; Schafhausen P; Brummendorf TH
    Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
    Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
    Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
    Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosutinib.
    Keller G; Schafhausen P; Brümmendorf TH
    Recent Results Cancer Res; 2010; 184():119-27. PubMed ID: 20072835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
    Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
    Redaelli S; Boschelli F; Perini P; Pirola A; Viltadi M; Gambacorti-Passerini C
    Leukemia; 2010 Jun; 24(6):1223-7. PubMed ID: 20445575
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
    Keller-V Amsberg G; Brümmendorf TH
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1121-7. PubMed ID: 23098112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
    Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
    Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
    Trask PC; Cella D; Besson N; Kelly V; Masszi T; Kim DW
    Leuk Res; 2012 Apr; 36(4):438-42. PubMed ID: 22036634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on dual Src/Abl inhibitors.
    Musumeci F; Schenone S; Brullo C; Botta M
    Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V; Wang A; Prescott H
    Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosutinib treatment for Philadelphia chromosome-positive leukemias.
    Bethelmie-Bryan B; Lord K; Holloway S; Khoury HJ
    Future Oncol; 2014 Feb; 10(2):179-85. PubMed ID: 24490604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
    Hill BG; Kota VK; Khoury HJ
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacology profile and clinical findings of bosutinib hydrate (Bosulif® Tablets)].
    Tahara M; Shibata A; Katsura S
    Nihon Yakurigaku Zasshi; 2016 May; 147(5):311-8. PubMed ID: 27181728
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
    Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.